HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
1. A lyophilized human papillomavirus vaccine (HPV) formulation comprising:
a) a therapeutically effective amount of HPV virus-like particles (VLPs) of at least one HPV type which are adsorbed onto an aluminum adjuvant wherein the VLPs of each HPV type are present in a concentration of 10-200 mcg/ml and wherein the VLPs are selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, and HPV82; and;
b) 4% to 7% w/v mannitol and 1% to 5% w/v sucrose; and
c) optionally a salt,
wherein the formulation is stable for a time period of 6 months at 25° C. and for a time period of 3 months at 37° C. following lyophilization, wherein the formulation is stable if the HPV VLPs retain potency over the time period at the indicated temperature, as measured in a Biacore assay.
2. The formulation of claim 1 , further comprising about 0.15 M to about 0.32M NaCl.
3. The formulation of claim 2 , further comprising about 5 mM to about 20 mM histidine.
4. The formulation of claim 3 , further comprising about 0.01% to about 0.03% weight to volume concentration of a surfactant selected from the group consisting of Polysorbate 20 and Polysorbate 80.
5. The formulation of claim 4 , wherein the surfactant is Polysorbate 80 which is present in a weight to volume concentration of about 0.01%.
6. The formulation of claim 1 , wherein the aluminum adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, and aluminum hydroxyphosphate.
7. The formulation of claim 6 , wherein the HPV VLPs are from HPV types 6, 11, 16 and 18.
8. The formulation of claim 7 , further comprising HPV VLPs of at least one additional HPV type selected from the group consisting of: 31, 33, 45, 52 and 58.
9. A lyophilized human papillomavirus vaccine (HPV) formulation comprising:
a) a therapeutically effective amount of HPV virus-like particles (VLPs) of at least four HPV types which are adsorbed onto an aluminum adjuvant, wherein the VLPs of each HPV type are present in a concentration of 10-200 mcg/ml and wherein the VLPs are selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, and HPV82; and;
b) 4% to 7% w/v mannitol and 1% to 5% w/v sucrose; and
c) optionally a salt,
wherein the formulation is stable for a time period of 6 months at 25° C. and for a time period of 3 months at 37° C. following lyophilization, wherein the formulation is stable if the HPV VLPs retain potency over the time period at the indicated temperature, as measured in a Biacore assay.
10. A lyophilized human papillomavirus vaccine (HPV) formulation comprising:
a) a therapeutically effective amount of HPV virus-like particles (VLPs) of at least six HPV types which are adsorbed onto an aluminum adjuvant, wherein the VLPs of each HPV type are present in a concentration of 10-200 mcg/ml and wherein the VIPs are selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, and HPV82; and;
b) 4% to 7% w/v mannitol and 1% to 5% w/v sucrose; and
c) optionally a salt,
wherein the formulation is stable for a time period of 6 months at 25° C and for a time period of 3 months at 37° C. following lyophilization, wherein the formulation is stable if the HPV VLPs retain potency over the time period at the indicated temperature, as measured in a Biacore assay.
11. A lyophilized human papillomavirus vaccine (HPV) formulation comprising:
a) a therapeutically effective amount of HPV virus-like particles (VIPs) of at least nine. HPV types which are adsorbed onto an aluminum adjuvant, wherein the VLPs of each HPV type are present in a concentration of 10-200 mcg/ml and wherein the VLPs are selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73, and HPV82; and;
b) 4% to 7% w/v mannitol and 1% to 5% w/v sucrose; and
c) optionally a salt,
wherein the formulation is stable for a time period of 6 months at 25° C. and for a time period of 3 months at 37° C following lyophilization, wherein the formulation is stable if the HPC VLPs retain potency over the time period at the indicated temperature, as measured in a Biacore assay.